Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Core Viewpoint - Biofrontera Inc. will report its financial results for Q4 and the full year of 2025 on March 19, 2026, and will host a conference call to discuss these results and provide a business update [1]. Group 1: Financial Reporting - The financial results for the three months and full year ended December 31, 2025, will be reported after the close of U.S. financial markets on March 19, 2026 [1]. - A conference call is scheduled for March 19, 2026, at 10:00 a.m. Eastern Time to discuss the financial results and answer questions [2]. Group 2: Company Overview - Biofrontera is a U.S.-based biopharmaceutical company that specializes in the treatment of dermatological conditions, focusing on photodynamic therapy (PDT) [3]. - The company commercializes Ameluz, a drug-device combination used for PDT of Actinic Keratosis, which are pre-cancerous skin lesions [3]. - Biofrontera is conducting clinical trials to expand the use of its products for treating non-melanoma skin cancers and moderate-to-severe acne [3].